Cardiovascular Systems Inc

Cardiovascular Systems — Q3 FY2020 Earnings Presentation

7 slides from Cardiovascular Systems's earnings presentation, May 5, 2020

  1. Slide 1: Q3 FY20 Earnings Call May 5, 2020

    Q3 FY20 Earnings Call May 5, 2020

  2. Slide 2: Safe Harbor: Forward Looking Statements

    Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem

  3. Slide 3: Q3 Revenues of $61.2 Million, 3% Decrease

    Q3 Revenues of $61.2 Million 3% Decrease Revenues US Coronary revenue ($ in millions) declined 2% Drivers US Peripheral revenue Unit sold decreased 9% as declined 6% COVID-19 negatively impacted procedure Drivers US volumes Units sold decreased 6% as Peripheral, US Coronary, Support product revenue

  4. Slide 4: Financial Results

    Q3 FY20 Financial Results ($ in millions) Worldwide Peripheral Revenue Worldwide Coronary Revenue $48.3 $47.6 $20.8 $45.2 $45.5 $20.0 $19.0 $42.6 $18.2 $18.5 6% 2% decline growth WW in WW in Q3 Q3 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Gross Margin Cash and M

  5. Slide 5: Highlights: Financial, Operational Peripheral and Coronary

    Q3 FY20 Highlights Financial Operational - Peripheral Operational – Coronary Other Revenues Decreased -3.4% vs. LY • Low profile peripheral offerings • Growing adoption of coronary • Sold 20,000 OAS units including Exchangeable and toolkit featuring OAS with • Certified 66 international Gross Margin

  6. Slide 6: Near-term Financial Commentary

    Near-term Financial Commentary • CSI withdrew fiscal 2020 financial guidance on April 1, 2020 due to the impact of COVID-19 on US procedure volumes • Our April US procedure volumes declined 53% vs. LY • Several factors may increase or decrease our procedure volumes during the last two months of Q4,

  7. Slide 7: Investor Contact

    Investor Contact: Jack Nielsen 651-202-4919 [email protected] CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2020 Cardiovascular Systems, Inc. CSII OrbusNeich®, Teleport® and Sapphire® are trademarks

Cardiovascular Systems — Q3 FY2020 Earnings Presentation on 6ix